AI-empowered Pipeline-in-a-drug Option: Insilico Medicine Nominates ISM9077, Potential First-in-class Target Y Inhibitor, as Preclinical Candidate (PCC) for Ocular Diseases, Inflammatory Disorders and Aging
As a dual-purpose, potential first-in-class, "pipeline-in-a-drug" candidate, ISM9077 provides an innovative solution for ocular diseases, inflammatory disorders, and the fundamental aging process. ISM9077 was designed, evaluated and optimized utilizing Chemistry42's integrated generative...
Covered in this story
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.